Reduning Injection versus Neuraminidase Inhibitors in the Treatment of Influenza: A Systematic Review and Meta-Analysis.
10.1007/s11655-022-3524-9
- Author:
Guo-Zhen ZHAO
1
;
Bo LI
2
;
Ya-Fan WANG
2
;
Shi-Qi GUO
3
;
Yuan DU
1
;
Qiu-Xiao MA
4
;
Yu-Hong GUO
2
;
Qing-Quan LIU
5
,
6
Author Information
1. School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
2. Department of Emergency, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.
3. School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China.
4. Department of Respiratory, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
5. Department of Emergency, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China. liuqingquan2003@
6. com.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
Reduning Injection;
influenza;
meta-analysis;
systematic review
- MeSH:
Humans;
Neuraminidase;
Influenza, Human/drug therapy*;
Drugs, Chinese Herbal;
Antiviral Agents
- From:
Chinese journal of integrative medicine
2022;28(11):1023-1031
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To perform a systematic review to assess the effectiveness and safety of Reduning Injection versus neuraminidase inhibitors in treatment of influenza.
METHODS:The MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Bio-medical Literature and Retrieval System (Sinomed), China National Knowledge Infrastructure Database (CNKI), China Science and Technology Journal Database (VIP), Wanfang Data Knowledge Service Platform and ClinicalTrails.gov were systematically searched from inception dates to May 2021 for randomized controlled trials (RCTs) exploring Reduning Injection alone or in combination with neuraminidase inhibitors in patients with influenza. Statistical analysis was performed using RevMan 5.4 and Stata 15.1. The qualities of the involved studies were assessed by the risk of bias according to the Cochrane handbook. The evidence quality of each outcome was evaluated by GRADEpro GDT.
RESULTS:Twelve trials with 1,460 patients were included. The included studies had a certain unclear or high risk of bias. Reduning Injection appeared to be more effective in shortening the fever clearance time (MD: -16.20 h, 95% CI: -19.40 to -12.99, 7 trials, 814 patients, I2=94%, very low certainty), fever alleviation time (MD: -4.09 h, 95% CI: -4.22 to -3.96, 3 trials, 366 patients, I2=0%, low certainty), cough alleviation time (MD: -21.34 h, 95% CI: -41.56 to -1.11, 2 trials, 228 patients, I2=89%, very low certainty), fatigue alleviation time (MD: -31.83 h, 95% CI: -36.88 to -26.77, 2 trials, 270 patients, I2=0%, low certainty), sore throat alleviation time (MD: -28.66 h, 95% CI: -32.23 to -25.10, 1 trial, 150 patients, low certainty), and improving the total effective rate (RR: 1.15, 95% CI: 1.06 to 1.25, 10 trials, 1,074 patients, I2=76%, very low certainty). Besides, Reduning Injection seemed generally safe.
CONCLUSIONS:This study provided low or very low evidence indicating Reduning Injection may be effective in the treatment of influenza and might be safe. Further rigorously designed studies are needed to confirm the effectiveness and safety of Reduning Injection and support it as a recommendation for influenza.
